抗VEGF治疗RVO合并的黄斑水肿的研究进展
Study Progress of Unti-VEGF Treatment of Macular Edema Induced by Retinal Vein Occlusion

DOI: 10.12677/HJO.2015.42008, PP. 42-46

Keywords: 黄斑水肿，视网膜静脉阻塞，抗VEGF治疗，联合治疗
Macular Edema, Retinal Vein Occlusion, Anti-VEGF Treatment, Combined Treatment

Full-Text   Cite this paper   Add to My Lib

Abstract:

视网膜静脉阻塞(retinal vein occlusion, RVO)是仅次于糖尿病性视网膜病变的常见视网膜血管疾病,是致盲的主要原因之一。黄斑水肿(macular edema)是RVO视力损害的最主要的原因。因此黄斑水肿的治疗是RVO治疗中最重要的内容，近年来抗VEGF药物的出现为黄斑水肿的治疗提供了一种新的治疗手段，目前大量研究证实无论是在消除或者减轻黄斑水肿方面，还是在提高视力方面，玻璃体腔内注射抗VEGF药物治疗RVO黄斑水肿都是有确切疗效的。本文就近年来有关RVO合并的黄斑水肿的抗VEGF治疗研究进展综述如下。
Retinal vein occlusion (RVO) is a common disease to cause blindness, which incidence is only next to diabetic retinopathy. The macular edema is the cause of vision loses. Therefore, the treatment of macular edema is one of the most important contents of RVO treatment. In recent years, the emergence of anti-VEGF drugs for the treatment of macular edema provides a new method. At present, a large of studies confirm whether in terms of eliminate or relieve the macular edema, or in terms of improving eyesight. Vitreous injection of anti-VEGF drug has exact curative effect. This paper reviews the recent advances in anti-VEGF treatment of macular edema secondary to retinal vein occlusion.

References

[1]	Salam, A., Da Costa, J. and Sivaprasad, S. (2010) Anti-vascular endothelial growth factor agents for diabetic maculo-pathy. British Journal of Ophthalmology, 94, 821-826.
[2]	Ojima, T., Takagi, H., Suzuma, K., et al. (2006) EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. The American Journal of Pathology, 168, 331-339.
[3]	Keane, P.A. and Sadda, S.R. (2011) Retinal vein occlusion and macular edema-critical evaluation of the clinical value of ranibizumab. Clinical Ophthalmology, 5, 771-781.
[4]	Pece, A., Isola, V., Piermarocchi, S., et al. (2011) Efficacy and safety of antivascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Ranibizumab) for naive retinal vein occlusion: 1-year follow-up. British Journal of Ophthalmology, 95, 56-68.
[5]	Noma, H., Minamoto, A., Funatsu, H., Tsukamoto, H., Nakano, K., Yamashita, H., et al. (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefe’s Archive for Clinical and Experimental Ophthalmology, 244, 309-315.
[6]	Noma, H., Funatsu, H., Yamasaki, M., Tsukamoto, H., Mimura, T., Sone, T., et al. (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond), 22, 42-48.
[7]	Park, S.P. and Ahn, J.K. (2009) Changes of aqueous vascular endothelial growth factor and pigment epithelium-de- rived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clinical Experimental Ophthalmology, 37, 490-495.
[8]	Hufendiek, K., Hufendiek, K., Panagakis, G., et al. (2012) Visual and morphological outcomes of bevacizumab (Avastin) versus ranibizumab (Lucentis) treatment for retinal angiomatous proliferation. International Ophthalmology, 32, 259-268.
[9]	Ciulla, T.A. and Rosenfeld, P.J. (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Current Opinion in Ophthalmology, 20, 166-174.
[10]	Wroblewski, J.J., Wells 3rd, J.A., Adamis, A.P., Buggage, R.R., Cunningham, E.T., Goldbaum, M., et al. (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology, 127, 374- 380.
[11]	Wroblewski, J.J., Wells III, J.A. and Gonzales, C.R. (2010) Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American Journal of Ophthalmology, 149, 147-154.
[12]	Rosenfeld, P.J., Fung, A.E. and Puliafito, C.A. (2005) Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surgery Lasers and Imaging, 36, 336-339.
[13]	Jaissle, G.B., Ziemssen, F., Petermeier, K., Szurman, P., Ladewig, M., Gelisken, F., et al. (2006) Beva-cizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmology, 103, 471-475.
[14]	Epstein, D.L., Algvere, P.V., von Wendt, G., Seregard, S. and Kvanta, A. (2012) Bevacizumab for macular edema in central retinal vein occlusion: A prospective, randomized, double-masked clinical study. Ophthalmology, 119, 1184- 1189.
[15]	Kriechbaum, K., Michels, S., Prager, F., Georgopoulos, M., Funk, M., Geitzenauer, W. and Schmidt-Erfurth, U. (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study. British Journal of Ophthalmology, 92, 518-522.
[16]	Brown, D.M., Campochiaro, P.A., Singh, R.P., Li, Z., Gray, S., Saroj, N., et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion: Six month primary end point results of a phase III study. Ophthalmology, 117, 1124-1133.e1.
[17]	Kinge, B., Stordahl, P.B., Forsaa, V., Fossen, K., Haugstad, M., Helgesen, O.H., et al. (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: Results from the sham-controlled ROCC study. American Journal of Ophthalmology, 150, 310-314.
[18]	Shima, D.T., Adamis, A.P., Ferrara, N., Yeo, K.T., Yeo, T.K., Allende, R., et al. (1995) Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Molecular Medicine, 1, 182-193.
[19]	Park, S.P. and Ahn, J.K. (2009) Changes of aqueous vascular endothelial growth factor and pigment epithelium-de- rived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clinical Experimental Ophthalmology, 37, 490-495.
[20]	Salinas-Alamán, A., Zarranz-Ventura, J., Caire González-Jauregui, J.M., Sádaba-Echarri, L.M., Barrio-Barrio, J. and García-Layana, A. (2010) Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. European Journal of Ophthalmology, 21, 434-439.
[21]	张雪岩, 李艳波, 周黎纹, 王晓波, 罗向东 (2014) 玻璃体腔注射雷珠单抗联合激光光凝治疗 BRVO 合并黄斑水肿. 国际眼科杂志, 4, 747-749.

Full-Text